Notice for vanzacaftor / tezacaftor / deutivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)
Active ingredients
vanzacaftor / tezacaftor / deutivacaftor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
film‐coated tablet; granules
Indication
For the treatment of cystic fibrosis
Therapeutic area
Respiratory